Pentanedioic acid bis-[(2-aminoethyl)amide] | 98577-77-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Pentanedioic acid bis-[(2-aminoethyl)amide]
• 英文别名: N,N'-bis(2-aminoethyl)pentanediamide
• CAS: 98577-77-6
• 化学式: C₉H₂₀N₄O₂
• 分子量: 216.283
• InChiKey: LGALZBAHDKJWHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9-氯吖啶 、 Pentanedioic acid bis-[(2-aminoethyl)amide] 以 various solvent(s) 为溶剂， 反应 3.0h， 生成 N,N'-Bis(2-(9-acridinylamino)ethyl)pentanediamide
  参考文献：
  名称：

  Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives

  摘要：

  A series of amide-linked triacridines of varying interchromophore separation were synthesized as potential DNA trisintercalating agents. The corresponding diamide diacridines (lacking the central chromophore) were also prepared, and the DNA-binding and biological activities of both series of compounds were evaluated. Although one of the triacridines shows evidence of a trisintercalative binding mode, most of the triacridines (and all the diacridines) bound by bisintercalation. The diacridines showed great cytotoxicity and higher DNA association constants than the corresponding 9-[[3-(dimethylamino)propyl]amino]acridine monomer, but addition of a third chromophore did not provide corresponding increases in either DNA affinity, inhibition of RNA synthesis, or cytotoxicity. Some members of both series show minimal in vivo antileukemic activity. The results suggest that further development of trimeric molecules as potential antitumor agents should focus on smaller chromophores with lower capacity for nonspecific binding and/or the employment of rigid linker chains to provide true molecular "staples" for DNA.

  DOI：

  10.1021/jm00151a011
• 作为产物：
  描述：

  {2-[4-(2-Benzyloxycarbonylamino-ethylcarbamoyl)-butyrylamino]-ethyl}-carbamic acid benzyl ester 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 Pentanedioic acid bis-[(2-aminoethyl)amide]
  参考文献：
  名称：

  Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives

  摘要：

  A series of amide-linked triacridines of varying interchromophore separation were synthesized as potential DNA trisintercalating agents. The corresponding diamide diacridines (lacking the central chromophore) were also prepared, and the DNA-binding and biological activities of both series of compounds were evaluated. Although one of the triacridines shows evidence of a trisintercalative binding mode, most of the triacridines (and all the diacridines) bound by bisintercalation. The diacridines showed great cytotoxicity and higher DNA association constants than the corresponding 9-[[3-(dimethylamino)propyl]amino]acridine monomer, but addition of a third chromophore did not provide corresponding increases in either DNA affinity, inhibition of RNA synthesis, or cytotoxicity. Some members of both series show minimal in vivo antileukemic activity. The results suggest that further development of trimeric molecules as potential antitumor agents should focus on smaller chromophores with lower capacity for nonspecific binding and/or the employment of rigid linker chains to provide true molecular "staples" for DNA.

  DOI：

  10.1021/jm00151a011

文献信息

• Novel therapeutic agents for membrane transporters
  申请人：——

  公开号：US20030044845A1

  公开（公告）日：2003-03-06

  Novel multi-binding compounds (agents) are disclosed which bind cell membrane transporters including ion channels, molecular transporters and ion pumps. The compounds of this invention comprise from 2 to 10 ligands each of which can bind to such cellular transporters to modulate the biological processes/functions thereof. Each of the ligands is covalently attached to a linker (framework) to provide for a multi-binding compound. The linker is selected such that the multi-binding compound exhibits increased modulation of the biological processes/functions of the transporter as compared to the aggregate of the individual ligand units made available for binding to the transporter.

  本发明揭示了一种新型多重结合化合物（试剂），其结合细胞膜转运体，包括离子通道、分子转运体和离子泵。本发明的化合物包括2到10个配体，每个配体都可以结合到这些细胞转运体上，以调节其生物过程/功能。每个配体都共价地连接到一个连接器（框架）上，以提供多重结合化合物。所选择的连接器是为了使多重结合化合物相比可用于结合转运体的单个配体单元的聚合体表现出增强的调节转运体的生物过程/功能的特性。
• Novel therapeutic agents for macromolecular structures
  申请人：——

  公开号：US20030060663A1

  公开（公告）日：2003-03-27

  Disclosed are novel multibinding compounds (agents) which bind macromolecular structures including cellular, extracellular, and microbial components derived from vectors, viruses, fungi, yeasts, bacteria, and the like. The compounds of this invention comprise a plurality of ligands each of which can bind to such macromolecular structures thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker (framework) to provide for the multibinding compound. The linker is selected such that the multibinding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of cell as compared to the aggregate of the individual units of the ligand.

  本发明公开了一种新型的多结合化合物（药剂），其能够结合向量、病毒、真菌、酵母、细菌等细胞、细胞外和微生物成分的大分子结构。本发明的化合物包括多种配体，每种配体均能结合此类大分子结构，从而调节其生物过程/功能。每个配体都与连接体（框架）共价连接，以形成多结合化合物。所选择的连接体使得构建的多结合化合物相对于配体的单个单位的聚集体表现出增加的细胞生物过程/功能调节或干扰。
• Methods for identifying novel multimeric agents that modulate receptors
  申请人：——

  公开号：US20030087306A1

  公开（公告）日：2003-05-08

  Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

  本发明揭示了新型的多重结合化合物（试剂），其能够结合细胞受体。本发明的化合物包括多个配体，每个配体都能够结合到这些细胞受体上，从而调节其生物过程/功能。每个配体均与一个连接剂或连接剂共价结合，这些连接剂可以相同或不同，以提供多重结合化合物。所选择的连接剂使得所构建的多重结合化合物表现出对细胞生物过程/功能的增强调节或干扰。本发明还揭示了一种识别能够结合细胞受体的新型多重结合化合物的方法，以及一种生成这种新型多重结合化合物混合物的方法。
• Novel therapeutic agents that modulate enzymatic processes
  申请人：——

  公开号：US20040023290A1

  公开（公告）日：2004-02-05

  Novel multi-binding compounds are disclosed that modulate enzymatic processes. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an enzyme, enzyme substrate or enzyme cofactor thereby modulating the biological processes/functions thereof.

  本发明揭示了一种多重结合化合物，可调节酶过程。该发明的化合物包括2-10个共价连接的配体，每个配体都能够结合到酶、酶底物或酶辅因子上，从而调节其生物过程/功能。
• 带有双端胺基的酰胺类化合物及其制备方法和应用
  申请人：[en]GUANGDONG FRESHYOU BIOTECHNOLOGY CO., LTD;[zh]广东香与生物科技有限公司

  公开号：WO2024050715A1

  公开（公告）日：2024-03-14

  本申请提供一种带有双端胺基的酰胺类化合物，具有通式(I)。其中，A和B独立地选自取代或未取代的C1～C18亚烷基、C2～C18亚烯基、C2～C18亚炔基、C6～C18亚芳基、C5～C18亚杂芳基或其任意组合。本申请还提供所述酰胺类化合物的制备方法和应用。